Atezolizumab in Metastatic Urothelial Carcinoma Outside Clinical Trials: Focus on Efficacy, Safety, and Response to Subsequent Therapies

被引：0
|
作者：
Pedro C. Barata
Dhrmesh Gopalakrishnan
Vadim S. Koshkin
Prateek Mendiratta
Matt Karafa
Kimberly Allman
Allison Martin
Jennifer Beach
Pam Profusek
Allison Tyler
Laura Wood
Moshe Ornstein
Timothy Gilligan
Brian I. Rini
Jorge A. Garcia
Petros Grivas
机构：
[1] Taussig Cancer Institute Cleveland Clinic,Department of Hematology & Medical Oncology
[2] Cleveland Clinic,Department of Hospital Medicine
[3] Cleveland Clinic,Quantitative Health Sciences
[4] University of Washington and Fred Hutchinson Cancer Research Center,Department of Medicine, Division of Oncology
[5] Seattle Cancer Care Alliance,undefined
来源：
Targeted Oncology | 2018年 / 13卷
关键词：
D O I：
暂无
中图分类号：
学科分类号：
摘要：
引用
收藏
页码：353 / 361
页数：8
相关论文
共 50 条
  • [41] PATIENTS (PTS) WITH METASTATIC RENAL CELL CARCINOMA (MRCC) RECEIVING ANGIOGENESIS INHIBITOR (AIS) THERAPIES: TREATMENT EFFICACY AND SAFETY IN CLINICAL PRACTICE
    McDermott, D.
    Choueiri, T. K.
    Clement, J.
    Brick, A. J.
    Kwabi, C.
    Shah, K.
    Banerjee, A.
    Duh, M. S.
    Neary, M. P.
    Oh, W. K.
    ANNALS OF ONCOLOGY, 2008, 19 : 190 - 191
  • [42] Drug adherence monitoring in clinical trials: a necessity for a correct assessment of the efficacy and safety of antihypertensive therapies
    Burnier, Michel
    Wuerzner, Gregoire
    JOURNAL OF HYPERTENSION, 2015, 33 (12) : 2395 - 2398
  • [43] Efficacy and safety of antibody-drug conjugates in the treatment of urothelial cell carcinoma: a systematic review and meta-analysis of prospective clinical trials
    Ren, Jun-Wei
    Chen, Ze-Yu
    Bai, Yun-Jin
    Han, Ping
    FRONTIERS IN PHARMACOLOGY, 2024, 15
  • [44] Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (vol 25, pg 1706, 2019)
    Powles, Thomas
    Kockx, Mark
    Rodriguez-Vida, Alejo
    Duran, Ignacio
    Crabb, Simon J.
    van der Heijden, Michiel S.
    Szabados, Bernadett
    Pous, Albert Font
    Gravis, Gwenaelle
    Herranz, Urbano Anido
    Protheroe, Andrew
    Ravaud, Alain
    Maillet, Denis
    Mendez, Maria Jose
    Suarez, Cristina
    Linch, Mark
    Prendergast, Aaron
    van Dam, Pieter-Jan
    Stanoeva, Diana
    Daelemans, Sofie
    Mariathasan, Sanjeev
    Tea, Joy S.
    Mousa, Kelly
    Banchereau, Romain
    Castellano, Daniel
    NATURE MEDICINE, 2023, 29 (12) : 3271 - 3271
  • [45] Clinical efficacy and biomarker analysis of neoadjuvant atezolizumab in operable urothelial carcinoma in the ABACUS trial (vol 25, pg 1706, 2019)
    Powles, Thomas
    Kockx, Mark
    Rodriguez-Vida, Alejo
    Duran, Ignacio
    Crabb, Simon J.
    Van Der Heijden, Michiel S.
    Szabados, Bernadett
    Pous, Albert Font
    Gravis, Gwenaelle
    Herranz, Urbano Anido
    Protheroe, Andrew
    Ravaud, Alain
    Maillet, Denis
    Mendez, Maria Jose
    Suarez, Cristina
    Linch, Mark
    Prendergast, Aaron
    van Dam, Pieter-Jan
    Stanoeva, Diana
    Daelemans, Sofie
    Mariathasan, Sanjeev
    Tea, Joy S.
    Mousa, Kelly
    Banchereau, Romain
    Castellano, Daniel
    NATURE MEDICINE, 2020, 26 (06) : 983 - 983
  • [46] Atezolizumab (atezo) in patients with metastatic urothelial carcinoma (mUC): A 2-year clinical update from a phase Ia study.
    Petrylak, Daniel Peter
    Powles, Thomas
    Bellmunt, Joaquim
    Braiteh, Fadi S.
    Loriot, Yohann
    Morales, Rafael
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35 (06)
  • [47] Exposure-response safety analysis of avelumab in patients with locally advanced or metastatic urothelial carcinoma.
    Li, Jerry
    Bello, Carlo
    Khandelwal, Akash
    Vugmeyster, Yulia
    Nickens, Dana
    Lin, Swan
    CANCER RESEARCH, 2021, 81 (13)
  • [48] Use of early dynamics of clinical and laboratory parameters to predict resistance in patients with metastatic urothelial carcinoma receiving post-platinum atezolizumab
    Graser, Christopher
    McDonald, Thomas O.
    Sonpavde, Guru
    Michor, Franziska
    CANCER RESEARCH, 2024, 84 (06)
  • [49] Atezolizumab (atezo) in platinum-treated locally advanced or metastatic urothelial carcinoma (mUC): Safety analysis from an expanded access study.
    Bellmunt, Joaquim
    Pal, Sumanta K.
    Zheng, Hanzhe
    Tayama, Darren
    Chang, Dannis
    Hoffman-Censits, Jean H.
    JOURNAL OF CLINICAL ONCOLOGY, 2017, 35
  • [50] Atezolizumab in Platinum-treated Locally Advanced or Metastatic Urothelial Carcinoma: Clinical Experience from an Expanded Access Study in the United States
    Pal, Sumanta Kumar
    Hoffman-Censits, Jean
    Zheng, Hanzhe
    Kaiser, Constanze
    Tayama, Darren
    Bellmunt, Joaquim
    EUROPEAN UROLOGY, 2018, 73 (05) : 800 - 806
12345